search for


Updates of Radioiodine Treatment for Graves’ Disease
Int J Thyroidol 2019;12(2):85-90
Published online November 30, 2019;
© 2019 Korean Thyroid Association.

Shin Young Jeong

Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
Correspondence to: Shin Young Jeong, MD, PhD, Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, 807 Hoguk-ro, Buk-gu, Daegu 41404, Korea
Tel: 82-53-200-2852, Fax: 82-53-200-3419, E-mail:
Received September 24, 2019; Revised October 18, 2019; Accepted October 27, 2019.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Radioiodine (RAI) has been used for the treatment of hyperthyroidism and is usually administered orally as sodium iodide (I-131) in solution or a capsule. However, this results in RAI being rapidly incorporated into the thyroid cells, and extensive local tissue damage occurring via beta emissions of I-131. The incidence rate of hypothyroidism is 5-50% at the first year after RAI therapy and is positively associated with the dosage of RAI. RAI has been used since 1960 in Korea; however, there have been few well-designed prospective trials, leaving many questions about indications, optimal dose, efficacy, and side-effects. This review summarizes the latest research pertaining to clinical questions about indications, optimal dose, efficacy, and side-effects.
Keywords : Radioactive iodine, Graves’ disease, Thyroid, Hyperthyroidism

November 2019, 12 (2)